StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Travere Therapeutics's EV/EBITDA was 201.1× on Nov 11, 2026.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026201.1×–

More Travere Therapeutics figures

See a number that looks wrong?